MGH today announced the five-year, $30 million deal with pharmaceutical giant Johnson & Johnson to bring to the experimental test to market. The technology uses a microchip to detect tiny traces of cancer cells in the blood.
The new test is being heralded as potentially "revolutionary," viewed as a way to track the spread or remission of cancers in patients, and eventually, as a potential screening tool for people who don't have cancer. Still, Dr. Toner says, at the moment, this remains "a very early technology."
This program aired on January 3, 2011. The audio for this program is not available.